Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis

Area of Science:

• Biomedical research
• Rheumatology
• Oncology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and is also implicated in rheumatoid arthritis (RA).
• Endostatin, a known angiogenesis inhibitor, has demonstrated efficacy as an anti-tumor agent.
• The pathological mechanisms of cancer neoangiogenesis share similarities with rheumatoid arthritis, suggesting potential therapeutic overlap.

Purpose of the Study:

• To investigate the therapeutic potential of human recombinant endostatin in treating rheumatoid arthritis (RA).
• To evaluate the effects of endostatin on human RA synovial tissue using a SCID-HuRAg mouse model.

Main Methods:

• Human recombinant endostatin (10 or 50 mg/kg) was administered via direct intrasynovial injection into SCID-HuRAg mice bearing human RA synovial grafts.
• Synovial tissue volume and histological changes were assessed 7 days post-injection.
• Control groups received phosphate-buffered saline.

Main Results:

• Endostatin administration significantly reduced the volume of grafted synovial tissue in a dose-dependent manner.
• A significant decrease in inflammatory cell infiltration (macrophages, lymphocytes) was observed.
• Vascularity, assessed by von Willebrand factor VIII and type IV collagen, was reduced, with increased apoptosis in RA synovia.

Conclusions:

• Anti-angiogenesis treatment with endostatin demonstrates potential as a novel therapeutic strategy for rheumatoid arthritis.
• The findings support the exploration of endostatin for RA treatment, targeting its angiogenic component.